Clinical trial · Interventional
Effects of Prolonged Continuous Theta Burst Stimulation in Chemotherapy-induced Peripheral Neuropathy
Effects of Prolonged Continuous Theta Burst Stimulation in Chemotherapy-induced Peripheral Neuropathy: a Randomized Cross- Over Trial
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Laboratory studies have shown that prolonged continuous theta burst stimulation (pcTBS) provides better pain relief than 10 Hz repetitive transcranial magnetic stimulation (rTMS), with a shorter stimulation time, making it more practical for clinical use. Chemotherapy-induced peripheral neuropathy often causes neuropathic pain in cancer patients. The aims of this study are: 1. To compare the effects of pcTBS and 20 Hz rTMS on chemotherapy-induced peripheral neuropathy; 2. To compare the effects of pcTBS applied to the primary motor cortex versus the dorsolateral prefrontal cortex on neuropathic pain as well as depression and anxiety.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer Females | Breast Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| 20 Hz rTMS | Device | — | UNRESOLVED |
| prolonged continuous TBS | Device | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- prolonged continuous TBS (pcTBS)
- description
- pcTBS over M1
- interventionNames
- Device: prolonged continuous TBS
- type
- ACTIVE_COMPARATOR
- label
- 20 Hz rTMS
- description
- 20 Hz rTMS over M1
- interventionNames
- Device: 20 Hz rTMS
Primary outcomes (1)
- measure
- visual analogue pain scale (VAS pain scale)
- timeFrame
- baseline, pre-intervention and immediately after completion the intervention and at 4 weeks follow-up
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * breast cancer patients aged between 18- and 80-years-old with CIPN * history of receiving chemotherapy including taxane-based neurotoxic agents * with neuropathic pain, score≥3 in a 0-10 VAS pain scale. * with fair cognition and can cooperate to evaluate pain severity. * neither at end-stage cancer nor at the estimated survival time less than 6 months. Exclusion Criteria: * brain tumor or history of epilepsy * intracranial metallic devices, artificial cochleae, pacemakers, or any other metal device * recent myocardial ischemia or unstable angina * severe cognitive dysfunction or pregnancy * injuries or fractures in the part of neuropathic pain
References
Publications (0)
Data not yet available